PERSPECTA

News from every angle

← Back to headlines

Adial Pharma faces governance risks and dilution ahead of 2026 shareholder vote

Adial Pharma is confronting governance risks and significant dilution as a 2026 shareholder vote on preferred conversions and warrants approaches.

17 Aug, 06:30 — 17 Aug, 06:30
PostShare

Sources

Showing 1 of 1 sources
globe-and-mailHigh4d ago

Adial Pharma Faces Governance Risks and Major Dilution as 2026 Shareholder Vote Looms on Preferred Conversions and Warrants - The Globe and Mail

Adial Pharma Faces Governance Risks and Major Dilution as 2026 Shareholder Vote Looms on Preferred Conversions and Warrants  The Globe and Mail

Read full article →

Related Stories

UK Reports Unexpected £1.8 Billion Deficit in July Ahead of New Chancellor's Budget

16m ago

UK Retail Sales Decline in July Following World Cup Boost

26m ago

Chinese Court Accepts Evergrande Unit Liquidation Petition

29m ago

Aveanna Healthcare Prices 15 Million Share Secondary Offering

33m ago